Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP trimmed its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 9.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,784 shares of the company’s stock after selling 1,939 shares during the quarter. Wellington Management Group LLP’s holdings in Amphastar Pharmaceuticals were worth $660,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in AMPH. Smartleaf Asset Management LLC raised its position in Amphastar Pharmaceuticals by 222.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after acquiring an additional 493 shares during the period. Parkside Financial Bank & Trust lifted its position in shares of Amphastar Pharmaceuticals by 806.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock valued at $36,000 after acquiring an additional 871 shares in the last quarter. TD Private Client Wealth LLC boosted its stake in shares of Amphastar Pharmaceuticals by 22.7% in the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock worth $78,000 after acquiring an additional 388 shares during the last quarter. KBC Group NV increased its position in shares of Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after purchasing an additional 650 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in Amphastar Pharmaceuticals by 90.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,203 shares of the company’s stock valued at $156,000 after purchasing an additional 1,992 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Trading Up 1.1 %

NASDAQ AMPH opened at $24.42 on Tuesday. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The stock has a market capitalization of $1.16 billion, a P/E ratio of 8.14, a PEG ratio of 2.19 and a beta of 0.79. The firm’s 50-day moving average is $28.51 and its two-hundred day moving average is $37.90. Amphastar Pharmaceuticals, Inc. has a 12 month low of $22.74 and a 12 month high of $53.96.

Insider Activity

In related news, CFO William J. Peters sold 4,231 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares of the company’s stock, valued at $2,681,377.02. This represents a 4.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 27.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on AMPH shares. Piper Sandler dropped their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research note on Friday, March 21st. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.